Germany’s Federal Institute for Drugs and Medical Devices (BfArM) approved the Company’s (NRSN) Clinical Trial Application (CTA) to enroll patients in PARADIGM, its Phase 2b study of its lead combination drug candidate PrimeC in the treatment of amyotrophic lateral sclerosis (ALS).